More than 150,000 Americans will likely die of lung cancer this year. It's estimated that only 25 percent of lung cancer patients are good candidates for traditional surgery. In the past, removal of the surgery option was essentially a death sentence. But that's all changed thanks to the non-invasive, low-stress treatments offered through the use of CyberKnife. The CyberKnife's accurate delivery of high dose radiation has caught the attention of many oncologists and thoracic surgeons.
According to the system manufacturer Accuray, the number of lung cancer patients treated with CyberKnife radiosurgery in the United States grew 52 percent from calendar year 2007 to 2008 -- and 43 percent worldwide.
This significant growth is due in part to the increased availability of lung cancer treatments at CyberKnife centers, of which there are now 164 worldwide. Many of the centers feature the Synchrony® Respiratory Tracking System, which continuously synchronizes radiation beam delivery with the motion of the tumor, and the Xsight® Lung Tracking System, which uses the body's internal anatomy to precisely track lung tumors non-invasively.
"In cancer care, the paradigm is shifting toward less invasive treatment alternatives that exhibit fewer risks, fewer side effects and decreased recovery times," says Euan S. Thomson, M.D., president and CEO of Accuray. "The rapid increase in lung cancer patients treated with our system proves that this is a reality. More and more patients are opting for CyberKnife radiosurgery as a non-invasive means of treating their cancer and maintaining their quality of life."